@dennismccain @Long_Life I think $MRNA has to say they do not think their work is affected by the $ABUS patent. Any other kind of statement is exhibit A in the damages case. They would never have spent the likely $MILLION+ or so to challenge the patent validity if it didn’t affect their work. Period. The likelihood of a buyout or settlement on possibly hundreds of billions in revenue would be far more than simply to buy $ABUS for $1B. Which makes $ABUS an attractive investment right now. It will likely run up until exact settlement is released. Which could come Monday morning, as Phase 3 supposed to begin Monday. Otherwise injunction. Also coincidence they announce over a weekend that they receive gov money near the market cap of $ABUS?
  • 1
@Science_Trader @Long_Life I believe you’re reading too much into this. ABUS stock went up initially on the potential liability but later I read that the patent does not interfere and the stock of ABUS fell Friday. The market vetted the seriousness in just one day. And no one is going to stop the forward movement of a potential vaccine. As for the hundreds of billions in revenue, well, Pfizer and AstraZeneca already squashed that. Their willingness to sell the vaccine for $20 per dose has taken all the profit out. So even if the revenues seem large, the profits won’t. And it’s hard to sue for a portion of the profits when the product is being sold at cost.
  • 1
1 Like